Cargando…

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

AIM: Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) and insulin combination therapy is an effective treatment option for type 2 diabetes, but long‐term data are lacking. The aim was to assess the long‐term efficacy of the GLP‐1RA liraglutide in subgroups by insulin use in the LEADER trial. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tack, Cees J., Jacob, Stephan, Desouza, Cyrus, Bain, Stephen C., Buse, John B., Nauck, Michael A., Petrie, John R., Poulter, Neil R., Pratley, Richard E., Stegmann, Helen Vanya B. K., Bosch‐Traberg, Heidrun, Startseva, Elena, Zinman, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852575/ https://www.ncbi.nlm.nih.gov/pubmed/31282028 http://dx.doi.org/10.1111/dom.13826

Ejemplares similares

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial
por: Nauck, Michael A., et al.
Publicado: (2018)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2020)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ
por: Rutten, Guy E. H. M., et al.
Publicado: (2016)

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials
por: Kahkoska, Anna R., et al.
Publicado: (2020)

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial
por: Petrie, John R., et al.
Publicado: (2016)

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
por: Kiyosue, Arihiro, et al.
Publicado: (2017)

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015)

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
por: Steinberg, William M., et al.
Publicado: (2014)

Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
por: Amod, Aslam, et al.
Publicado: (2019)

Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)
por: Amod, Aslam, et al.
Publicado: (2020)

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
por: Brown‐Frandsen, Kirstine, et al.
Publicado: (2019)

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
por: Zinman, Bernard, et al.
Publicado: (2009)

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial
por: Kaneko, Shizuka, et al.
Publicado: (2018)

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
por: Nauck, Michael A., et al.
Publicado: (2020)

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
por: Zinman, Bernard, et al.
Publicado: (2017)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
por: Rossing, Peter, et al.
Publicado: (2023)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
por: Pieber, Thomas R., et al.
Publicado: (2017)

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial
por: Seino, Yutaka, et al.
Publicado: (2016)

Confronting Subtle Workplace Mistreatment: The Importance of Leaders as Allies
por: Schneider, Kimberly T., et al.
Publicado: (2017)

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
por: Pratley, Richard E., et al.
Publicado: (2019)

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial
por: Kaku, Kohei, et al.
Publicado: (2015)

Glycemic and metabolic sub-classification of prediabetes and risk factors for cardiovascular disease in the D2d cohort
por: Kashyap, Sangeeta R., et al.
Publicado: (2023)

Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes
por: Buse, John B., et al.
Publicado: (2021)

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
por: Masmiquel, L., et al.
Publicado: (2016)

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
por: Rossing, Peter, et al.
Publicado: (2023)

Label-Free Detection of Insulin and Glucagon within Human Islets of Langerhans Using Raman Spectroscopy
por: Hilderink, Janneke, et al.
Publicado: (2013)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes
por: Nunez Lopez, Yury O., et al.
Publicado: (2018)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
por: Nauck, M.
Publicado: (2016)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
por: Nauck, Michael A., et al.
Publicado: (2011)

Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE
por: Klein, Klara R, et al.
Publicado: (2021)

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
por: Nathan, David M., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ugvd5l8l2o3p2ci0d8inq7i746